轻型卒中的血管内取栓:我们应把标准降到多低?
这项回顾性多中心队列研究纳入214例前循环大血管闭塞且NIHSS<6的轻型卒中患者,比较血管内取栓与药物治疗的疗效与安全性。结果显示取栓组与药物组在90天mRS 0-1和0-2均无显著差异,但取栓组症状性颅内出血率更高(5.8% vs 0%,P=0.02)。仅在M1闭塞中观察到取栓获益信号(P=0.07),作者认为需进一步随机对照试验评估。
要点
- 轻型卒中(NIHSS<6)大血管闭塞取栓与药物组90天mRS 0-1无显著差异(55.7% vs 54.4%,aOR 1.3,95%CI 0.64-2.64,P=0.47)。
- 取栓组症状性颅内出血率高于药物组(5.8% vs 0%,P=0.02)。
- 仅M1闭塞亚组取栓获益接近显著(P=0.07),需进一步随机对照试验评估。
核心结论
- 回顾性多中心队列显示,轻型卒中(NIHSS<6)接受取栓无论血栓位置如何,均未改善优秀或独立功能结局,且症状性颅内出血率增加。
- 这与指南推荐NIHSS≥6行取栓一致;仅在M1闭塞中观察到取栓获益信号,但需未来随机对照试验进一步评估。
研究设计与样本
- 研究为回顾性队列, pooled 来自美国与西班牙8个中心、2012年1月至2017年3月间前循环大血管闭塞且NIHSS<6、距最后正常时间24小时内就诊的患者。
- 共纳入214例,其中取栓组124例、药物治疗组90例。
- 主要结局为90天mRS 0-1,次要结局为mRS 0-2,安全结局为症状性颅内出血;采用多因素logistic回归调整年龄、就诊NIHSS、最后正常至就诊时间、中心、静脉阿替普酶、Alberta卒中项目早期CT评分及血栓位置,并进行倾向性评分匹配作为敏感性分析,按血栓位置分层。
主要发现
- 取栓组与药物组90天mRS 0-1无差异(55.7% vs 54.4%;调整OR 1.3,95%CI 0.64-2.64,P=0.47)。
- 取栓组与药物组90天mRS 0-2无差异(63.3% vs 67.8%;调整OR 0.9,95%CI 0.43-1.88,P=0.77)。
- 倾向性匹配分析62对中无治疗效应(取栓组53.5% vs 药物组48.4%;OR 1.17,95%CI 0.54-2.52,P=0.69)。
- 按任何血栓位置分层均无统计学显著差异;M1闭塞接近显著(P=0.07)。
- 取栓组症状性颅内出血率高于药物组(5.8% vs 0%;P=0.02)。
临床怎么用
- 原文结论指出,该结果与指南推荐NIHSS≥6行取栓一致;作者认为仅在M1闭塞中存在取栓获益信号,但需未来随机对照试验进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Endovascular thrombectomy (EVT) is effective for acute ischemic stroke with large vessel occlusion and National Institutes of Health Stroke Scale (NIHSS) ≥6. However, EVT benefit for mild deficits large vessel occlusions (NIHSS, <6) is uncertain. We evaluated EVT efficacy and safety in mild strokes with large vessel occlusion. Methods- A retrospective cohort of patients with anterior circulation large vessel occlusion and NIHSS <6 presenting within 24 hours from last seen normal were pooled. Patients were divided into 2 groups: EVT or medical management. Ninety-day mRS of 0 to 1 was the primary outcome, mRS of 0 to 2 was the secondary. Symptomatic intracerebral hemorrhage was the safety outcome. Clinical outcomes were compared through a multivariable logistic regression after adjusting for age, presentation NIHSS, time last seen normal to presentation, center, IV alteplase, Alberta Stroke Program early computed tomographic score, and thrombus location. We then performed propensity score matching as a sensitivity analysis. Results were also stratified by thrombus location. Results- Two hundred fourteen patients (EVT, 124; medical management, 90) were included from 8 US and Spain centers between January 2012 and March 2017. The groups were similar in age, Alberta Stroke Program early computed tomographic score, IV alteplase rate and time last seen normal to presentation. There was no difference in mRS of 0 to 1 between EVT and medical management (55.7% versus 54.4%, respectively; adjusted odds ratio, 1.3; 95% CI, 0.64-2.64; P=0.47). Similar results were seen for mRS of 0 to 2 (63.3% EVT versus 67.8% medical management; adjusted odds ratio, 0.9; 95% CI, 0.43-1.88; P=0.77). In a propensity matching analysis, there was no treatment effect in 62 matched pairs (53.5% EVT, 48.4% medical management; odds ratio, 1.17; 95% CI, 0.54-2.52; P=0.69). There was no statistically significant difference when stratified by any thrombus location; M1 approached significance ( P=0.07). Symptomatic intracerebral hemorrhage rates were higher with thrombectomy (5.8% EVT versus 0% medical management; P=0.02). Conclusions- Our retrospective multicenter cohort study showed no improvement in excellent and independent functional outcomes in mild strokes (NIHSS, <6) receiving thrombectomy irrespective of thrombus location, with increased symptomatic intracerebral hemorrhage rates, consistent with the guidelines recommending the treatment for NIHSS ≥6. There was a signal toward benefit with EVT only in M1 occlusions; however, this needs to be further evaluated in future randomized control trials.
引用
- Sarraj A, Hassan A, Savitz SI, et al. Endovascular Thrombectomy for Mild Strokes: How Low Should We Go? Stroke. 2018. PMID: 30355094. doi:10.1161/STROKEAHA.118.022114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。